Truist analyst David MacDonald lowered the firm’s price target on Pennant Group (PNTG) to $32 from $38 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as “mixed”, with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNTG:
- Pennant Group names Brent Guerisoli chairman
- Pennant Group initiated with an Equal Weight at Wells Fargo
- Pennant Group, Kno2 enter strategic partnership for patient care
- Pennant Group management to meet with Oppenheimer
- Pennant Group Reports Robust Third-Quarter Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
